StockNews.AI
NTRA
StockNews.AI
147 days

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

1. Natera will present DEFINE-HT study results at ISHLT 2025 meeting. 2. The study may impact donor-derived cell-free DNA testing in heart transplants.

2m saved
Insight
Article

FAQ

Why Bullish?

The presentation of results from a significant study could enhance Natera’s reputation and market position, similar to how positive study results propelled stock increases for other biotech firms like Illumina after major presentations.

How important is it?

The upcoming presentation signifies Natera's commitment to innovation in the healthcare field, suggesting a strong potential for future growth in their offerings.

Why Long Term?

Results from the DEFINE-HT study, relevant for broader applications, can influence NTRA’s stock positively over time as they could lead to increased adoption of their testing solutions.

Related Companies

ILMNGHDXPACB
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as.

Related News